APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Breakthrough Therapies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Breakthrough Therapies Market Outlook and Growth Opportunities 2026

Report ID 174082110415 April 2026Not stated

Choose your research edition.

Industry ResearchBreakthrough Therapies Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Breakthrough Therapies Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Breakthrough Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Breakthrough Therapies Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Breakthrough Therapies Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Breakthrough Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Breakthrough Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Breakthrough Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Breakthrough Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Breakthrough Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Breakthrough Therapies market include F. Hoffmann-La Roche, Merck & Co., Bristol-Myers Squibb, Novartis, AstraZeneca, Johnson & Johnson, Pfizer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Breakthrough Therapies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Breakthrough Therapies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Breakthrough Therapies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Breakthrough Therapies market.

Breakthrough Therapies Segment by Company

F. Hoffmann-La Roche

Merck & Co.

Bristol-Myers Squibb

Novartis

AstraZeneca

Johnson & Johnson

Pfizer

AbbVie

Breakthrough Therapies Segment by Type

Targeted Therapy

Immunotherapy

Gene Therapy

Cell Therapy

Other

Breakthrough Therapies Segment by Application

Cardiovascular

Central Nervous System and Neurology

Rare Diseases

Oncology

Others

Breakthrough Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Breakthrough Therapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Breakthrough Therapies key companies, revenue, market share, and recent developments.

3. To split the Breakthrough Therapies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Breakthrough Therapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Breakthrough Therapies significant trends, drivers, influence factors in global and regions.

6. To analyze Breakthrough Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Breakthrough Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Breakthrough Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Breakthrough Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Breakthrough Therapies industry.

Chapter 3: Detailed analysis of Breakthrough Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Breakthrough Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Breakthrough Therapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Breakthrough Therapies Industry Trends Table 2. Breakthrough Therapies Industry Drivers Table 3. Breakthrough Therapies Industry Opportunities and Challenges Table 4. Breakthrough Therapies Industry Restraints Table 5. Global Breakthrough Therapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Breakthrough Therapies Revenue Share by Company (2021-2026) Table 7. Global Breakthrough Therapies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Breakthrough Therapies Key Company Manufacturing Base & Headquarters Table 9. Global Breakthrough Therapies Company, Product Type & Application Table 10. Global Breakthrough Therapies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Breakthrough Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Targeted Therapy Table 15. Significant Companies of Immunotherapy Table 16. Significant Companies of Gene Therapy Table 17. Significant Companies of Cell Therapy Table 18. Significant Companies of Other Table 19. Global Breakthrough Therapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Breakthrough Therapies Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Breakthrough Therapies Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Breakthrough Therapies Sales Value Share by Type (2021-2026) Table 23. Global Breakthrough Therapies Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Cardiovascular Table 25. Significant Companies of Central Nervous System and Neurology Table 26. Significant Companies of Rare Diseases Table 27. Significant Companies of Oncology Table 28. Significant Companies of Others Table 29. Global Breakthrough Therapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Breakthrough Therapies Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Breakthrough Therapies Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Breakthrough Therapies Sales Value Share by Application (2021-2026) Table 33. Global Breakthrough Therapies Sales Value Share by Application (2027-2032) Table 34. Global Breakthrough Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Breakthrough Therapies Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Breakthrough Therapies Sales Value Share by Region (2021-2026) Table 37. Global Breakthrough Therapies Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Breakthrough Therapies Sales Value Share by Region (2027-2032) Table 39. Global Breakthrough Therapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Breakthrough Therapies Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Breakthrough Therapies Sales Value Market Share by Country (2021-2026) Table 42. Global Breakthrough Therapies Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Breakthrough Therapies Sales Value Market Share by Country (2027-2032) Table 44. F. Hoffmann-La Roche Company Information Table 45. F. Hoffmann-La Roche Business Overview Table 46. F. Hoffmann-La Roche Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. F. Hoffmann-La Roche Breakthrough Therapies Product Portfolio Table 48. F. Hoffmann-La Roche Recent Development Table 49. Merck & Co. Company Information Table 50. Merck & Co. Business Overview Table 51. Merck & Co. Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Merck & Co. Breakthrough Therapies Product Portfolio Table 53. Merck & Co. Recent Development Table 54. Bristol-Myers Squibb Company Information Table 55. Bristol-Myers Squibb Business Overview Table 56. Bristol-Myers Squibb Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bristol-Myers Squibb Breakthrough Therapies Product Portfolio Table 58. Bristol-Myers Squibb Recent Development Table 59. Novartis Company Information Table 60. Novartis Business Overview Table 61. Novartis Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Novartis Breakthrough Therapies Product Portfolio Table 63. Novartis Recent Development Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AstraZeneca Breakthrough Therapies Product Portfolio Table 68. AstraZeneca Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Johnson & Johnson Breakthrough Therapies Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Breakthrough Therapies Product Portfolio Table 78. Pfizer Recent Development Table 79. AbbVie Company Information Table 80. AbbVie Business Overview Table 81. AbbVie Breakthrough Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. AbbVie Breakthrough Therapies Product Portfolio Table 83. AbbVie Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Breakthrough Therapies Product Image Figure 2. Global Breakthrough Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Breakthrough Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Breakthrough Therapies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Targeted Therapy Image Figure 8. Immunotherapy Image Figure 9. Gene Therapy Image Figure 10. Cell Therapy Image Figure 11. Other Image Figure 12. Global Breakthrough Therapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Breakthrough Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Breakthrough Therapies Sales Value Share by Type (2021-2032) Figure 15. Cardiovascular Image Figure 16. Central Nervous System and Neurology Image Figure 17. Rare Diseases Image Figure 18. Oncology Image Figure 19. Others Image Figure 20. Global Breakthrough Therapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Breakthrough Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Breakthrough Therapies Sales Value Share by Application (2021-2032) Figure 23. Global Breakthrough Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Breakthrough Therapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Breakthrough Therapies Sales Value (2021-2032) & (US$ Million) Figure 26. North America Breakthrough Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Breakthrough Therapies Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Breakthrough Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Breakthrough Therapies Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Breakthrough Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Breakthrough Therapies Sales Value (2021-2032) & (US$ Million) Figure 32. South America Breakthrough Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Breakthrough Therapies Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Breakthrough Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Breakthrough Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Immunotherapy
  • Gene Therapy
  • Cell Therapy
  • Other
Applications
  • Cardiovascular
  • Central Nervous System and Neurology
  • Rare Diseases
  • Oncology
  • Others
Companies covered
  • F. Hoffmann-La Roche
  • Merck & Co.
  • Bristol-Myers Squibb
  • Novartis
  • AstraZeneca
  • Johnson & Johnson
  • Pfizer
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Breakthrough Therapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Breakthrough Therapies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Breakthrough Therapies Market Dynamics
  1. 2.1 Breakthrough Therapies Industry Trends
  2. 2.2 Breakthrough Therapies Industry Drivers
  3. 2.3 Breakthrough Therapies Industry Opportunities and Challenges
  4. 2.4 Breakthrough Therapies Industry Restraints
3 Breakthrough Therapies Market by Company
  1. 3.1 Global Breakthrough Therapies Company Revenue Ranking in 2025
  2. 3.2 Global Breakthrough Therapies Revenue by Company (2021-2026)
  3. 3.3 Global Breakthrough Therapies Company Ranking (2024-2026)
  4. 3.4 Global Breakthrough Therapies Company Manufacturing Base and Headquarters
  5. 3.5 Global Breakthrough Therapies Company Product Type and Application
  6. 3.6 Global Breakthrough Therapies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Breakthrough Therapies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Breakthrough Therapies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Breakthrough Therapies Market by Type
  1. 4.1 Breakthrough Therapies Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Immunotherapy
  4. 4.1.3 Gene Therapy
  5. 4.1.4 Cell Therapy
  6. 4.1.5 Other
  7. 4.2 Global Breakthrough Therapies Sales Value by Type
  8. 4.2.1 Global Breakthrough Therapies Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Breakthrough Therapies Sales Value by Type (2021-2032)
  10. 4.2.3 Global Breakthrough Therapies Sales Value Share by Type (2021-2032)
5 Breakthrough Therapies Market by Application
  1. 5.1 Breakthrough Therapies Application Introduction
  2. 5.1.1 Cardiovascular
  3. 5.1.2 Central Nervous System and Neurology
  4. 5.1.3 Rare Diseases
  5. 5.1.4 Oncology
  6. 5.1.5 Others
  7. 5.2 Global Breakthrough Therapies Sales Value by Application
  8. 5.2.1 Global Breakthrough Therapies Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Breakthrough Therapies Sales Value by Application (2021-2032)
  10. 5.2.3 Global Breakthrough Therapies Sales Value Share by Application (2021-2032)
6 Breakthrough Therapies Regional Value Analysis
  1. 6.1 Global Breakthrough Therapies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Breakthrough Therapies Sales Value by Region (2021-2032)
  3. 6.2.1 Global Breakthrough Therapies Sales Value by Region: 2021-2026
  4. 6.2.2 Global Breakthrough Therapies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Breakthrough Therapies Sales Value (2021-2032)
  7. 6.3.2 North America Breakthrough Therapies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Breakthrough Therapies Sales Value (2021-2032)
  10. 6.4.2 Europe Breakthrough Therapies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Breakthrough Therapies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Breakthrough Therapies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Breakthrough Therapies Sales Value (2021-2032)
  16. 6.6.2 South America Breakthrough Therapies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Breakthrough Therapies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Breakthrough Therapies Sales Value Share by Country, 2025 VS 2032
7 Breakthrough Therapies Country-level Value Analysis
  1. 7.1 Global Breakthrough Therapies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Breakthrough Therapies Sales Value by Country (2021-2032)
  3. 7.2.1 Global Breakthrough Therapies Sales Value by Country (2021-2026)
  4. 7.2.2 Global Breakthrough Therapies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Breakthrough Therapies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Breakthrough Therapies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Breakthrough Therapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 F. Hoffmann-La Roche
  2. 8.1.1 F. Hoffmann-La Roche Company Information
  3. 8.1.2 F. Hoffmann-La Roche Business Overview
  4. 8.1.3 F. Hoffmann-La Roche Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 F. Hoffmann-La Roche Breakthrough Therapies Product Portfolio
  6. 8.1.5 F. Hoffmann-La Roche Recent Developments
  7. 8.2 Merck & Co.
  8. 8.2.1 Merck & Co. Company Information
  9. 8.2.2 Merck & Co. Business Overview
  10. 8.2.3 Merck & Co. Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co. Breakthrough Therapies Product Portfolio
  12. 8.2.5 Merck & Co. Recent Developments
  13. 8.3 Bristol-Myers Squibb
  14. 8.3.1 Bristol-Myers Squibb Company Information
  15. 8.3.2 Bristol-Myers Squibb Business Overview
  16. 8.3.3 Bristol-Myers Squibb Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Breakthrough Therapies Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Breakthrough Therapies Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Breakthrough Therapies Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Breakthrough Therapies Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Breakthrough Therapies Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Breakthrough Therapies Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst